Global CRISPR Fluorescence Assays Market Report 2026 | Capitalize on 19.5% CAGR to 2030 with Thermo Fisher, Merck, QIAGEN, and Mammoth Biosciences Driving Multiplex Diagnostics

What happened: ResearchAndMarkets.com added a CRISPR fluorescence assays global market report covering 2026 to 2030, featuring Thermo Fisher, Merck, QIAGEN, and Mammoth Biosciences. Key numbers: Market projected at $1.57 billion in 2025, $1.87 billion in 2026 (19.3% CAGR), and $3.83 billion by 2030 (19.5% CAGR). Why it matters: The report attributes forecast growth to multiplex and high-throughput assays, AI-enabled analysis platforms, and point-of-care diagnostics demand. OraSure's December 2024 acquisition of Sherlock Biosciences is cited as shaping the competitive landscape. Market: +1.9% today ($149.13), +41.1% YTD, 0.4x vol — as of 15:32 UTC Verified: Q3_2026 (Oct 29) EPS $2.49 vs $2.09 est, +19.3% beat; next print ~Jan 28

ResearchAndMarkets.com added a CRISPR fluorescence assays global market report covering 2026 to 2030, featuring Thermo Fisher, Merck, QIAGEN, and Mammoth Biosciences.

The report attributes forecast growth to multiplex and high-throughput assays, AI-enabled analysis platforms, and point-of-care diagnostics demand. OraSure's December 2024 acquisition of Sherlock Biosciences is cited as shaping the competitive landscape. Market: +1.9% today ($149.13), +41.1% YTD, 0.4x vol — as of 15:32 UTC Verified: Q3_2026 (Oct 29) EPS $2.49 vs $2.09 est, +19.3% beat; next print ~Jan 28